Table 11.
Oral equivalent doses based on ToxCast dosimetry and estimated urinary levels associated with oral doses.
| 2,4-D | BW (kg) | 24 hr urine volume (L) | In vitro-in vivo equivalent dose (mg/kg-d) | Scenario | Estimated urine level from oral dose (μg/L) |
|---|---|---|---|---|---|
| Children 4–12 | 30 | 0.66 | 0.014 | Lowest biologically relevant ToxCast assay result; highest predicted C ss | 636 |
| Adolescents | 55 | 1.7 | 0.014 | 453 | |
| Women | 55 | 1.6 | 0.014 | 481 | |
| Men | 70 | 1.7 | 0.014 | 576 | |
|
| |||||
| Children 4–12 | 30 | 0.66 | 0.028 | Lowest biologically relevant ToxCast assay result; average predicted C ss | 1273 |
| Adolescents | 55 | 1.7 | 0.028 | 906 | |
| Women | 55 | 1.6 | 0.028 | 963 | |
| Men | 70 | 1.7 | 0.028 | 1153 | |
|
| |||||
| MCPA | |||||
|
| |||||
| Children 4–12 | 30 | 0.66 | 0.01 | Lowest biologically relevant ToxCast assay result; highest predicted C ss | 455 |
| Adolescents | 55 | 1.7 | 0.01 | 324 | |
| Women | 55 | 1.6 | 0.01 | 344 | |
| Men | 70 | 1.7 | 0.01 | 412 | |
|
| |||||
| Children 4–12 | 30 | 0.66 | 0.0005 | Oral RfD | 23 |
| Adolescents | 55 | 1.7 | 0.0005 | 16 | |
| Women | 55 | 1.6 | 0.0005 | 17 | |
| Men | 70 | 1.7 | 0.0005 | 21 | |
|
| |||||
| Children 4–12 | 30 | 0.66 | 0.0044 | Oral RfD used by Health Canada; OPPTS | 200 |
| Adolescents | 55 | 1.7 | 0.0044 | 142 | |
| Women | 55 | 1.6 | 0.0044 | 151 | |
| Men | 70 | 1.7 | 0.0044 | 181 | |